FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308151337> ?p ?o ?g. }

• W4308151337 endingPage "100539" @default.
• W4308151337 startingPage "100539" @default.
• W4308151337 abstract "Post COVID-19 condition (PCC) is defined as symptoms lasting more than 12 weeks after developing COVID-19. Evidence of mitochondrial dysfunction has been reported in peripheral blood mononuclear cells obtained from patients with COVID-19. We hypothesized that PCC is caused by prolonged mitochondrial dysfunction. Given that coenzyme Q10 (CoQ10) can improve mitochondrial function, we examined whether high-dose CoQ10 can reduce the number and/or severity of PCC-related symptoms.In this placebo-controlled, double-blind, 2 × 2 crossover interventional trial, participants were recruited from two centres at Aarhus University Hospital and Gødstrup Hospital, Denmark. They were randomly assigned to receive either oral capsules of CoQ10 in a dose of 500 mg/day or placebo for 6 weeks, with crossover treatment after a 4-week washout period. The ED-5Q and a PCC-symptom specific questionnaire were completed by the participants at 5 visits during the 20-week study period. The primary endpoint was the change in the number and/or severity of PCC-related symptoms after the 6-week intervention compared to placebo. Participants who completed the two-dosing period were included in the primary analysis, while all participants receiving one dose were included in safety assessment.From May 25th, 2021, to September 22nd, 2021, 121 participants underwent randomization, and 119 completed both dosing periods - 59 and 60 in group A and B, respectively. At baseline, the mean PCC-related symptom score was 43.06 (95% CI: 40.18; 45.94), and the mean EQ-5D health index was 0.66 (95% CI: 0.64; 0.68). The difference between CoQ10 and placebo was not significant with respect to either the change in EQ-5D health index (with a mean difference of 0.01; 95% CI: -0.02; 0.04; p = 0.45) or the change in PCC-related symptom score (with a mean difference of -1.18; 95% CI: -3.54; 1.17; p = 0.32).Based on self-reported data, CoQ10 treatment does not appear to significantly reduce the number or severity of PCC-related symptoms when compared to placebo. However, we observed a significant spontaneous improvement on both scores regardless of treatment during 20 weeks observation.Placebo and CoQ10 capsules were provided by Pharma Nord, and the trial was supported by grants from the Novo Nordisk Foundation (NNF21OC0066984). This trial is registered with EudraCT, 2020-005961-16 and ClinicalTrials.gov, NCT04960215. The trial is completed." @default.
• W4308151337 created "2022-11-08" @default.
• W4308151337 creator A5015662519 @default.
• W4308151337 creator A5018917019 @default.
• W4308151337 creator A5020439804 @default.
• W4308151337 creator A5031584885 @default.
• W4308151337 creator A5057974583 @default.
• W4308151337 creator A5084791448 @default.
• W4308151337 creator A5086857457 @default.
• W4308151337 date "2023-01-01" @default.
• W4308151337 modified "2023-10-17" @default.
• W4308151337 title "High-dose coenzyme Q10 therapy versus placebo in patients with post COVID-19 condition: a randomized, phase 2, crossover trial" @default.
• W4308151337 cites W1520568691 @default.
• W4308151337 cites W1972130246 @default.
• W4308151337 cites W1990166011 @default.
• W4308151337 cites W2042157082 @default.
• W4308151337 cites W2093274439 @default.
• W4308151337 cites W2121629072 @default.
• W4308151337 cites W2137672734 @default.
• W4308151337 cites W2398570525 @default.
• W4308151337 cites W2606546819 @default.
• W4308151337 cites W3087262009 @default.
• W4308151337 cites W3095699680 @default.
• W4308151337 cites W3112559917 @default.
• W4308151337 cites W3126420006 @default.
• W4308151337 cites W3133517424 @default.
• W4308151337 cites W3134844657 @default.
• W4308151337 cites W3136955306 @default.
• W4308151337 cites W3153305267 @default.
• W4308151337 cites W3155316695 @default.
• W4308151337 cites W3194737219 @default.
• W4308151337 cites W3212354770 @default.
• W4308151337 cites W4210476933 @default.
• W4308151337 cites W4220662458 @default.
• W4308151337 cites W4220830275 @default.
• W4308151337 cites W4220947591 @default.
• W4308151337 cites W4224313552 @default.
• W4308151337 doi "https://doi.org/10.1016/j.lanepe.2022.100539" @default.
• W4308151337 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36337437" @default.
• W4308151337 hasPublicationYear "2023" @default.
• W4308151337 type Work @default.
• W4308151337 citedByCount "12" @default.
• W4308151337 countsByYear W43081513372023 @default.
• W4308151337 crossrefType "journal-article" @default.
• W4308151337 hasAuthorship W4308151337A5015662519 @default.
• W4308151337 hasAuthorship W4308151337A5018917019 @default.
• W4308151337 hasAuthorship W4308151337A5020439804 @default.
• W4308151337 hasAuthorship W4308151337A5031584885 @default.
• W4308151337 hasAuthorship W4308151337A5057974583 @default.
• W4308151337 hasAuthorship W4308151337A5084791448 @default.
• W4308151337 hasAuthorship W4308151337A5086857457 @default.
• W4308151337 hasBestOaLocation W43081513371 @default.
• W4308151337 hasConcept C126322002 @default.
• W4308151337 hasConcept C142724271 @default.
• W4308151337 hasConcept C168563851 @default.
• W4308151337 hasConcept C203092338 @default.
• W4308151337 hasConcept C204243189 @default.
• W4308151337 hasConcept C204787440 @default.
• W4308151337 hasConcept C27081682 @default.
• W4308151337 hasConcept C2777288759 @default.
• W4308151337 hasConcept C2779134260 @default.
• W4308151337 hasConcept C2779384338 @default.
• W4308151337 hasConcept C30036603 @default.
• W4308151337 hasConcept C3008058167 @default.
• W4308151337 hasConcept C524204448 @default.
• W4308151337 hasConcept C535046627 @default.
• W4308151337 hasConcept C71924100 @default.
• W4308151337 hasConcept C87813604 @default.
• W4308151337 hasConceptScore W4308151337C126322002 @default.
• W4308151337 hasConceptScore W4308151337C142724271 @default.
• W4308151337 hasConceptScore W4308151337C168563851 @default.
• W4308151337 hasConceptScore W4308151337C203092338 @default.
• W4308151337 hasConceptScore W4308151337C204243189 @default.
• W4308151337 hasConceptScore W4308151337C204787440 @default.
• W4308151337 hasConceptScore W4308151337C27081682 @default.
• W4308151337 hasConceptScore W4308151337C2777288759 @default.
• W4308151337 hasConceptScore W4308151337C2779134260 @default.
• W4308151337 hasConceptScore W4308151337C2779384338 @default.
• W4308151337 hasConceptScore W4308151337C30036603 @default.
• W4308151337 hasConceptScore W4308151337C3008058167 @default.
• W4308151337 hasConceptScore W4308151337C524204448 @default.
• W4308151337 hasConceptScore W4308151337C535046627 @default.
• W4308151337 hasConceptScore W4308151337C71924100 @default.
• W4308151337 hasConceptScore W4308151337C87813604 @default.
• W4308151337 hasLocation W43081513371 @default.
• W4308151337 hasLocation W43081513372 @default.
• W4308151337 hasLocation W43081513373 @default.
• W4308151337 hasLocation W43081513374 @default.
• W4308151337 hasLocation W43081513375 @default.
• W4308151337 hasOpenAccess W4308151337 @default.
• W4308151337 hasPrimaryLocation W43081513371 @default.
• W4308151337 hasRelatedWork W115784380 @default.
• W4308151337 hasRelatedWork W2072822165 @default.
• W4308151337 hasRelatedWork W2079171902 @default.
• W4308151337 hasRelatedWork W2243959385 @default.
• W4308151337 hasRelatedWork W2383935572 @default.
• W4308151337 hasRelatedWork W2423235166 @default.
• W4308151337 hasRelatedWork W2949506376 @default.

• next